Drug Profile
APL 1
Latest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator Apellis Pharmaceuticals
- Class Cyclic peptides
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Asthma; Chronic obstructive pulmonary disease
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for phase-I development in Asthma in United Kingdom (Inhalation)
- 28 Jul 2018 No recent reports of development identified for phase-I development in Chronic-obstructive-pulmonary-disease in United Kingdom (Inhalation)
- 02 Dec 2014 Phase-I clinical trials in Asthma in United Kingdom (Inhalation)